Optimization of the chicken chorioallantoic membrane assay as reliable in vivo model for the analysis of osteosarcoma.

Survival rates of osteosarcoma patients could not be significantly improved by conventional chemotherapeutic treatment regimens since the introduction of high-dose chemotherapy 35 years ago. Therefore, there is a strong clinical need for new therapeutic targets and personalized treatment strategies,...

Full description

Bibliographic Details
Main Authors: Pierre Kunz, Astrid Schenker, Heiner Sähr, Burkhard Lehner, Jörg Fellenberg
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2019-01-01
Series:PLoS ONE
Online Access:https://doi.org/10.1371/journal.pone.0215312
id doaj-cf0233012d6245ae92770967f977efdd
record_format Article
spelling doaj-cf0233012d6245ae92770967f977efdd2021-03-03T20:44:34ZengPublic Library of Science (PLoS)PLoS ONE1932-62032019-01-01144e021531210.1371/journal.pone.0215312Optimization of the chicken chorioallantoic membrane assay as reliable in vivo model for the analysis of osteosarcoma.Pierre KunzAstrid SchenkerHeiner SährBurkhard LehnerJörg FellenbergSurvival rates of osteosarcoma patients could not be significantly improved by conventional chemotherapeutic treatment regimens since the introduction of high-dose chemotherapy 35 years ago. Therefore, there is a strong clinical need for new therapeutic targets and personalized treatment strategies, requiring reliable in vivo model systems for the identification and testing of potential new treatment approaches. Conventional in vivo rodent experiments face ethical issues, are time consuming and costly, being of particular relevance in orphan diseases like osteosarcoma. An attractive alternative to such animal experiments is the chicken chorioallantoic membrane (CAM) assay. The CAM is a highly vascularized, non-innervated extra-embryonic membrane that is perfectly suited for the engraftment of tumor cells. However, only few reports are available for osteosarcoma and reported data are inconsistent. Therefore, the aim of this study was the adaptation and optimization of the CAM assay for its application in osteosarcoma research. Tumor take rates and volumes of osteosarcoma that developed on the CAM were analyzed after modification of several experimental parameters, including egg windowing, CAM pretreatment, inoculation technique and many more. Eight osteosarcoma cell lines were investigated. Our optimized OS-CAM-assay was finally validated against a rat animal xenograft model. Using the cell line MNNG HOS as reference we could improve the tumor take rates from 51% to 94%, the viability of the embryos from initially 40% to >80% and achieved a threefold increase of the tumor volumes. We were able to generate solid tumors from all eight osteosarcoma cell lines used in this study and could reproduce results that were obtained using an osteosarcoma rat animal model. The CAM assay can bridge the gap between in vitro cell culture and in vivo animal experiments. As reliable in vivo model for osteosarcoma research the optimized CAM assay may speed up preclinical data collection and simplifies research on potential new agents towards personalized treatment strategies. Further, in accordance with Russell's and Burch's "Principles of Humane Experimental Technique" the reasonable use of this model provides a refinement by minimizing pain and suffering of animals and supports a considerable reduction and/or replacement of animal experiments.https://doi.org/10.1371/journal.pone.0215312
collection DOAJ
language English
format Article
sources DOAJ
author Pierre Kunz
Astrid Schenker
Heiner Sähr
Burkhard Lehner
Jörg Fellenberg
spellingShingle Pierre Kunz
Astrid Schenker
Heiner Sähr
Burkhard Lehner
Jörg Fellenberg
Optimization of the chicken chorioallantoic membrane assay as reliable in vivo model for the analysis of osteosarcoma.
PLoS ONE
author_facet Pierre Kunz
Astrid Schenker
Heiner Sähr
Burkhard Lehner
Jörg Fellenberg
author_sort Pierre Kunz
title Optimization of the chicken chorioallantoic membrane assay as reliable in vivo model for the analysis of osteosarcoma.
title_short Optimization of the chicken chorioallantoic membrane assay as reliable in vivo model for the analysis of osteosarcoma.
title_full Optimization of the chicken chorioallantoic membrane assay as reliable in vivo model for the analysis of osteosarcoma.
title_fullStr Optimization of the chicken chorioallantoic membrane assay as reliable in vivo model for the analysis of osteosarcoma.
title_full_unstemmed Optimization of the chicken chorioallantoic membrane assay as reliable in vivo model for the analysis of osteosarcoma.
title_sort optimization of the chicken chorioallantoic membrane assay as reliable in vivo model for the analysis of osteosarcoma.
publisher Public Library of Science (PLoS)
series PLoS ONE
issn 1932-6203
publishDate 2019-01-01
description Survival rates of osteosarcoma patients could not be significantly improved by conventional chemotherapeutic treatment regimens since the introduction of high-dose chemotherapy 35 years ago. Therefore, there is a strong clinical need for new therapeutic targets and personalized treatment strategies, requiring reliable in vivo model systems for the identification and testing of potential new treatment approaches. Conventional in vivo rodent experiments face ethical issues, are time consuming and costly, being of particular relevance in orphan diseases like osteosarcoma. An attractive alternative to such animal experiments is the chicken chorioallantoic membrane (CAM) assay. The CAM is a highly vascularized, non-innervated extra-embryonic membrane that is perfectly suited for the engraftment of tumor cells. However, only few reports are available for osteosarcoma and reported data are inconsistent. Therefore, the aim of this study was the adaptation and optimization of the CAM assay for its application in osteosarcoma research. Tumor take rates and volumes of osteosarcoma that developed on the CAM were analyzed after modification of several experimental parameters, including egg windowing, CAM pretreatment, inoculation technique and many more. Eight osteosarcoma cell lines were investigated. Our optimized OS-CAM-assay was finally validated against a rat animal xenograft model. Using the cell line MNNG HOS as reference we could improve the tumor take rates from 51% to 94%, the viability of the embryos from initially 40% to >80% and achieved a threefold increase of the tumor volumes. We were able to generate solid tumors from all eight osteosarcoma cell lines used in this study and could reproduce results that were obtained using an osteosarcoma rat animal model. The CAM assay can bridge the gap between in vitro cell culture and in vivo animal experiments. As reliable in vivo model for osteosarcoma research the optimized CAM assay may speed up preclinical data collection and simplifies research on potential new agents towards personalized treatment strategies. Further, in accordance with Russell's and Burch's "Principles of Humane Experimental Technique" the reasonable use of this model provides a refinement by minimizing pain and suffering of animals and supports a considerable reduction and/or replacement of animal experiments.
url https://doi.org/10.1371/journal.pone.0215312
work_keys_str_mv AT pierrekunz optimizationofthechickenchorioallantoicmembraneassayasreliableinvivomodelfortheanalysisofosteosarcoma
AT astridschenker optimizationofthechickenchorioallantoicmembraneassayasreliableinvivomodelfortheanalysisofosteosarcoma
AT heinersahr optimizationofthechickenchorioallantoicmembraneassayasreliableinvivomodelfortheanalysisofosteosarcoma
AT burkhardlehner optimizationofthechickenchorioallantoicmembraneassayasreliableinvivomodelfortheanalysisofosteosarcoma
AT jorgfellenberg optimizationofthechickenchorioallantoicmembraneassayasreliableinvivomodelfortheanalysisofosteosarcoma
_version_ 1714820820588560384